Sarah Gwynne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Gwynne has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Chris Hurt
Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
7 shared publications - Maria A. Hawkins
Department of Medical Physics and Biomedical Engineering, University College London, UK
7 shared publications - John Staffurth
School of Medicine, Cardiff University, Cardiff, United Kingdom; Velindre University NHS Trust, Cardiff, United Kingdom
6 shared publications - Tom Crosby
Velindre University NHS Trust, Cardiff, UK
6 shared publications - Emiliano Spezi
School of Engineering, Cardiff University, Cardiff CF24 3AA, UK
5 shared publications G. Radhakrishna
Christie Hospital, The Christie NHS Foundation Trust, Manchester, UK
5 shared publications
Latest Publications
- 9 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104214
A novel technique for pain management to deliver a course of palliative radiotherapy
- 9 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104214
A novel technique for pain management to deliver a course of palliative radiotherapy
- 4 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 55, 104185
Chemoradiotherapy and Radiotherapy for Oesophageal Cancer in the UK: Current Practice and Future Directions: An Update
- 4 May 2026
- Published by Elsevier in Clinical Oncology
- Vol. 55, 104185
Chemoradiotherapy and Radiotherapy for Oesophageal Cancer in the UK: Current Practice and Future Directions: An Update
- 24 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104065
Variation in UK Oesophageal Radiotherapy Practice - Cause for Concern or Opportunity for Harmonisation?
- 24 January 2026
- Published by Elsevier in Clinical Oncology
- Vol. 52, 104065
Variation in UK Oesophageal Radiotherapy Practice - Cause for Concern or Opportunity for Harmonisation?
- 19 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104004
Royal College of Radiologists Guidance Statements on the Use of Auto-contouring in Radiotherapy
- 19 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104004
Royal College of Radiologists Guidance Statements on the Use of Auto-contouring in Radiotherapy
- 8 November 2025
- Published by Elsevier in Clinical Oncology
- Vol. 49, 103971
Quality Assurance in Multi-Modality Oesophago-Gastric Cancer Clinical Trials: Past, Present and Future Perspectives
- 8 November 2025
- Published by Elsevier in Clinical Oncology
- Vol. 49, 103971
Quality Assurance in Multi-Modality Oesophago-Gastric Cancer Clinical Trials: Past, Present and Future Perspectives
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103735
Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103735
Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?
- 15 November 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103693
Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent
- 15 November 2024
- Published by Elsevier in Clinical Oncology
- Vol. 37, 103693
Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent
- Open Access
- 3 September 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (1) , 10-18
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a surgical innovation deployed to treat peritoneal metastases. Traditionally, peritoneal metastases have been treated with systemic chemotherapy, but this approach is limited by poor peritoneal perfusion. Intra-abdominal chemotherapy in the form of heated lavage (hyperthermic intraperitoneal chemotherapy (HIPEC)) is currently used alongside cytoreductive surgery. The use of aerosolized agents in a laparoscopic setting was first described in 2000 in a swine model1; since then, a number of PIPAC studies have been reported. The IDEAL framework2 provides recommendations for the design, development, and reporting of studies for novel surgical interventions (Table 1). It recommends that innovations move through stages (idea, development, exploration, assessment, and long-term studies).
- 3 September 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (1) , 10-18
Open AccessPressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a surgical innovation deployed to treat peritoneal metastases. Traditionally, peritoneal metastases have been treated with systemic chemotherapy, but this approach is limited by poor peritoneal perfusion. Intra-abdominal chemotherapy in the form of heated lavage (hyperthermic intraperitoneal chemotherapy (HIPEC)) is currently used alongside cytoreductive surgery. The use of aerosolized agents in a laparoscopic setting was first described in 2000 in a swine model1; since then, a number of PIPAC studies have been reported. The IDEAL framework2 provides recommendations for the design, development, and reporting of studies for novel surgical interventions (Table 1). It recommends that innovations move through stages (idea, development, exploration, assessment, and long-term studies).
- Open Access
- 8 July 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1126) , 20210356
FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy
Objectives: Target volume delineation (TVD) has been identified as a weakness in the accuracy of radiotherapy, both within and outside of clinical trials due to the intra/interobserver variations affecting the TVD quality. Sources of variations such as poor compliance or protocol violation may have adverse effect on treatment outcomes. In this paper, we present and describe the FIELDRT software developed for the ARENA project to improve the quality of TVD through qualitative and quantitative feedbacks and individual and personalized summary of trainee”s performance. Methods: For each site-specific clinical case included in the FIELDRT software, reference volumes, minimum and maximum “acceptable” volumes and organ at risk were derived by outlines of consultants and senior trainees. The software components currently developed include: (a) user-friendly importing interface (b) analysis toolbox to compute quantitative and qualitative (c) visualiser and (d) structured report generator for personalised feedback. The FIELDRT software was validated by comparing the performance of 63 trainees and by measuring performance over time. In addition, a trainee evaluation day was held in 2019 to collect feedback on FIELDRT. Results: Results show the trainees’ improvement when reoutlining a case after reviewing the feedback generated from the FIELDRT software. Comments and feedback received after evaluation day were positive and confirmed that FIELDRT can be a useful application for training purposes. Conclusion: We presented a new open-source software to support education in TVD and ongoing continuous professional development for clinical oncology trainees and consultants. ARENA in combination with FIELDRT implements site-specific modules with reference target and organs at risk volumes and automatically evaluates individual performance using several quantitative and qualitative feedbacks. Pilot results suggests this software could be used as an education tool to reduce variation in TVD so to guarantee high quality in radiotherapy. Advances in knowledge: FIELDRT is a new easy and free to use software aiming at supporting education in TVD and ongoing continuous professional development. The software provides quantitative/qualitative feedback and an exportable report with an individual and personalised summary of trainee’s performance.
- 8 July 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1126) , 20210356
Open AccessFIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy
Objectives: Target volume delineation (TVD) has been identified as a weakness in the accuracy of radiotherapy, both within and outside of clinical trials due to the intra/interobserver variations affecting the TVD quality. Sources of variations such as poor compliance or protocol violation may have adverse effect on treatment outcomes. In this paper, we present and describe the FIELDRT software developed for the ARENA project to improve the quality of TVD through qualitative and quantitative feedbacks and individual and personalized summary of trainee”s performance. Methods: For each site-specific clinical case included in the FIELDRT software, reference volumes, minimum and maximum “acceptable” volumes and organ at risk were derived by outlines of consultants and senior trainees. The software components currently developed include: (a) user-friendly importing interface (b) analysis toolbox to compute quantitative and qualitative (c) visualiser and (d) structured report generator for personalised feedback. The FIELDRT software was validated by comparing the performance of 63 trainees and by measuring performance over time. In addition, a trainee evaluation day was held in 2019 to collect feedback on FIELDRT. Results: Results show the trainees’ improvement when reoutlining a case after reviewing the feedback generated from the FIELDRT software. Comments and feedback received after evaluation day were positive and confirmed that FIELDRT can be a useful application for training purposes. Conclusion: We presented a new open-source software to support education in TVD and ongoing continuous professional development for clinical oncology trainees and consultants. ARENA in combination with FIELDRT implements site-specific modules with reference target and organs at risk volumes and automatically evaluates individual performance using several quantitative and qualitative feedbacks. Pilot results suggests this software could be used as an education tool to reduce variation in TVD so to guarantee high quality in radiotherapy. Advances in knowledge: FIELDRT is a new easy and free to use software aiming at supporting education in TVD and ongoing continuous professional development. The software provides quantitative/qualitative feedback and an exportable report with an individual and personalised summary of trainee’s performance.
- 21 April 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (7) , e269-e280
SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography
- 21 April 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (7) , e269-e280
SCOPE 2 – Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography